Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Ardena acquires drug substance firm
by Rick Mullin
March 26, 2018
| A version of this story appeared in
Volume 96, Issue 13
Ardena, a Belgian drug services firm focused on finished-dose products, has acquired ChemConnection, a Dutch maker of active pharmaceutical ingredients (APIs) and nanomedicines. With the acquisition, Ardena will add process and analytical development services as well as capacity to make APIs in batches of up to 30 kg. ChemConnection was formed in 2012 when Merck & Co. spun off its Organon research division. The purchase will add 60 employees, bringing Ardena’s total to 200.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X